BRAF and colorectal carcinoma: It is worth noting that up to 60–70% of CRC tumors with mutated BRAF belong to the CMS1 subtype, also known as immune MSI, which is characterized by a high mutation rate, but a low prevalence of somatic copy number alterations (SCNAs).